GlassScriptPhysician profile
Thomas J Gould
NPI 1205153608
$11,750.58
in general payments reported to CMS, 2019-2025
51 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $1,990 · 2021: $2,472 · 2022: $2,070 · 2023: $1,760 · 2024: $1,059 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.01 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,402.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,288.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $842.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $627.67 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $612.56 | 2021-2025 | |
| Abbott Laboratories | $566.46 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx, Freestyle Libre |
| Takeda Pharmaceuticals U.S.A., INC. | $546.30 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $528.14 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $459.86 | 2019-2024 | Gardasil 9, Gardasil |
| Amgen INC. | $449.41 | 2019-2024 | Repatha |
| Pfizer INC. | $436.39 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.33 | 2019-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $411.35 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.87 | 2019-2022 | |
| Daiichi Sankyo INC. | $330.74 | 2019-2023 | Injectafer |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.